Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54


The estrogen pathway as a modulator of response to immunotherapy.

Velez MA, Burns TF, Stabile LP.

Immunotherapy. 2019 Sep;11(13):1161-1176. doi: 10.2217/imt-2019-0024. Epub 2019 Jul 30.


A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

Espinosa-Cotton M, Fertig EJ, Stabile LP, Gaither-Davis A, Bauman JE, Schmitz S, Gibson-Corley KN, Cheng Y, Jensen IJ, Badovinac VP, Laux D, Simons AL.

Biomark Res. 2019 Jul 16;7:14. doi: 10.1186/s40364-019-0164-0. eCollection 2019.


Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor Migration.

Singh M, Tian XJ, Donnenberg VS, Watson AM, Zhang J, Stabile LP, Watkins SC, Xing J, Sant S.

Cancer Res. 2019 Jun 1;79(11):2962-2977. doi: 10.1158/0008-5472.CAN-18-3151. Epub 2019 Apr 5.


Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer.

Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H, Deng S, Diao L, Wang J, Evans SE, Behrens C, Wistuba II, Fuqua SAW, Lin H, Stabile LP, Watowich SS, Kadara H, Moghaddam SJ.

Nat Commun. 2018 Nov 2;9(1):4589. doi: 10.1038/s41467-018-07042-y.


Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.

Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ.

Lung Cancer. 2018 Sep;123:91-98. doi: 10.1016/j.lungcan.2018.06.013. Epub 2018 Jun 22.


ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker.

Yoneyama T, Gorry M, Sobo-Vujanovic A, Lin Y, Vujanovic L, Gaither-Davis A, Moss ML, Miller MA, Griffith LG, Lauffenburger DA, Stabile LP, Herman J, Vujanovic NL.

J Cancer. 2018 Jun 23;9(14):2559-2570. doi: 10.7150/jca.24601. eCollection 2018.


The Role of the Estrogen Pathway in the Tumor Microenvironment.

Rothenberger NJ, Somasundaram A, Stabile LP.

Int J Mol Sci. 2018 Feb 19;19(2). pii: E611. doi: 10.3390/ijms19020611. Review.


Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.

Volonte D, Vyas AR, Chen C, Dacic S, Stabile LP, Kurland BF, Abberbock SR, Burns TF, Herman JG, Di YP, Galbiati F.

J Biol Chem. 2018 Feb 2;293(5):1794-1809. doi: 10.1074/jbc.M117.815902. Epub 2017 Dec 15.


Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.

Stabile LP, Farooqui M, Kanterewicz B, Abberbock S, Kurland BF, Diergaarde B, Siegfried JM.

J Thorac Oncol. 2018 Mar;13(3):399-412. doi: 10.1016/j.jtho.2017.11.126. Epub 2017 Dec 9.


Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates.

Yoneyama T, Gorry M, Miller MA, Gaither-Davis A, Lin Y, Moss ML, Griffith LG, Lauffenburger DA, Stabile LP, Herman JG, Vujanovic NL.

J Cancer. 2017 Oct 23;8(19):3916-3932. doi: 10.7150/jca.20779. eCollection 2017.


IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE.

Oral Oncol. 2017 Jun;69:38-45. doi: 10.1016/j.oraloncology.2017.03.011. Epub 2017 Apr 9.


The endocrine disrupting alkylphenols and 4,4'-DDT interfere with estrogen conversion and clearance by mouse liver cytosol.

El-Hefnawy T, Hernandez C, Stabile LP.

Reprod Biol. 2017 Sep;17(3):185-192. doi: 10.1016/j.repbio.2017.04.003. Epub 2017 May 19.


Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.

Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.


Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.

Siegfried JM, Farooqui M, Rothenberger NJ, Dacic S, Stabile LP.

Oncotarget. 2017 Apr 11;8(15):24063-24076. doi: 10.18632/oncotarget.16030.


Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.

Rothenberger NJ, Stabile LP.

Cancers (Basel). 2017 Apr 24;9(4). pii: E39. doi: 10.3390/cancers9040039. Review.


MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.

Gao X, Chen G, Gao C, Zhang DH, Kuan SF, Stabile LP, Liu G, Hu J.

Mol Oncol. 2017 Jun;11(6):628-639. doi: 10.1002/1878-0261.12055. Epub 2017 May 2.


Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.

Zhou J, Qu Z, Sun F, Han L, Li L, Yan S, Stabile LP, Chen LF, Siegfried JM, Xiao G.

Cancer Immunol Res. 2017 Mar;5(3):257-268. doi: 10.1158/2326-6066.CIR-16-0073. Epub 2017 Jan 20.


ATM protein is deficient in over 40% of lung adenocarcinomas.

Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP, Siegfried JM, Conrads TP, Smith NR, O'Connor MJ, Pierce AJ, Bakkenist CJ.

Oncotarget. 2016 Sep 6;7(36):57714-57725. doi: 10.18632/oncotarget.9757.


Survey for human polyomaviruses in cancer.

Toptan T, Yousem SA, Ho J, Matsushima Y, Stabile LP, Fernández-Figueras MT, Bhargava R, Ryo A, Moore PS, Chang Y.

JCI Insight. 2016 Feb;1(2). pii: e85562. Epub 2016 Feb 25.


Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.

Siegfried JM, Lin Y, Diergaarde B, Lin HM, Dacic S, Pennathur A, Weissfeld JL, Romkes M, Nukui T, Stabile LP.

Neoplasia. 2015 Nov;17(11):817-25. doi: 10.1016/j.neo.2015.11.002.


NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function.

Sun F, Qu Z, Xiao Y, Zhou J, Burns TF, Stabile LP, Siegfried JM, Xiao G.

Oncogene. 2016 May 5;35(18):2299-310. doi: 10.1038/onc.2015.299. Epub 2015 Aug 24.


Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Burns TF, Stabile LP.

Lung Cancer Manag. 2014 Feb 1;3(1):43-52.


Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.

Stabile LP, Rothstein ME, Gubish CT, Cunningham DE, Lee N, Siegfried JM.

J Thorac Oncol. 2014 Sep;9(9):1285-93. doi: 10.1097/JTO.0000000000000245.


Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.

Ng YK, Lee JY, Supko KM, Khan A, Torres SM, Berwick M, Ho J, Kirkwood JM, Siegfried JM, Stabile LP.

Melanoma Res. 2014 Jun;24(3):207-18. doi: 10.1097/CMR.0000000000000060.


Estrongenic steroid hormones in lung cancer.

Siegfried JM, Stabile LP.

Semin Oncol. 2014 Feb;41(1):5-16. doi: 10.1053/j.seminoncol.2013.12.009. Epub 2013 Dec 12. Review.


Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors.

Song JY, Siegfried JM, Diergaarde B, Land SR, Bowser R, Stabile LP, Dacic S, Dhir R, Nukui T, Romkes M, Weissfeld JL.

Cancer Epidemiol. 2013 Aug;37(4):518-22. doi: 10.1016/j.canep.2013.03.020. Epub 2013 Apr 23.


c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.

Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR.

Clin Cancer Res. 2013 Jan 15;19(2):380-92. doi: 10.1158/1078-0432.CCR-12-1555. Epub 2012 Dec 4. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3715. Thomas, Sufi [added].


Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.

Stabile LP, Rothstein ME, Cunningham DE, Land SR, Dacic S, Keohavong P, Siegfried JM.

Carcinogenesis. 2012 Nov;33(11):2181-9. doi: 10.1093/carcin/bgs260. Epub 2012 Aug 2. Erratum in: Carcinogenesis. 2013 Jun;34(6):1411.


Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP.

J Thorac Oncol. 2012 Mar;7(3):485-95. doi: 10.1097/JTO.0b013e31824177ea.


Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.

Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM.

Clin Cancer Res. 2011 Jul 1;17(13):4425-38. doi: 10.1158/1078-0432.CCR-10-3339. Epub 2011 May 27.


HGF-independent potentiation of EGFR action by c-Met.

Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM.

Oncogene. 2011 Aug 18;30(33):3625-35. doi: 10.1038/onc.2011.84. Epub 2011 Mar 21.


Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice.

Stabile LP, Rothstein ME, Keohavong P, Lenzner D, Land SR, Gaither-Davis AL, Kim KJ, Kaminski N, Siegfried JM.

Cancers (Basel). 2010 Dec 1;2(4):2153-70. doi: 10.3390/cancers2042153.


Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome.

Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR, Siegfried JM.

Clin Cancer Res. 2011 Jan 1;17(1):154-64. doi: 10.1158/1078-0432.CCR-10-0992. Epub 2010 Nov 9.


Estrogen receptor signaling in lung cancer.

Siegfried JM, Hershberger PA, Stabile LP.

Semin Oncol. 2009 Dec;36(6):524-31. doi: 10.1053/j.seminoncol.2009.10.004.


Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma.

Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP.

Clin Cancer Res. 2009 Nov 1;15(21):6529-40. doi: 10.1158/1078-0432.CCR-09-0862. Epub 2009 Oct 13.


HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.

Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM.

Clin Cancer Res. 2009 Jun 1;15(11):3740-50. doi: 10.1158/1078-0432.CCR-08-3252. Epub 2009 May 26.


Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.

Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, Shuai Y, Siegfried JM, Nichols M.

J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):102-9. doi: 10.1016/j.jsbmb.2009.05.004. Epub 2009 May 19.


Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.

Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte SM, Siegfried JM.

Lung Cancer. 2009 Apr;64(1):51-9. doi: 10.1016/j.lungcan.2008.07.002. Epub 2008 Aug 12.


Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.

Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, Dacic S, Luong TM, Kim KJ, Dulak AM, Siegfried JM.

Mol Cancer Ther. 2008 Jul;7(7):1913-22. doi: 10.1158/1535-7163.MCT-07-2169.


Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.

Siegfried JM, Gubish CT, Rothstein ME, Queiroz de Oliveira PE, Stabile LP.

Mol Pharmacol. 2007 Sep;72(3):769-79. Epub 2007 Jun 5.


Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.

Zhang W, Stabile LP, Keohavong P, Romkes M, Grandis JR, Traynor AM, Siegfried JM.

J Thorac Oncol. 2006 Sep;1(7):635-47.


Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells.

Myerburg MM, Latoche JD, McKenna EE, Stabile LP, Siegfried JS, Feghali-Bostwick CA, Pilewski JM.

Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1352-60. Epub 2007 Feb 16.


Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.

Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM.

Carcinogenesis. 2006 Aug;27(8):1547-55. Epub 2006 Mar 2.


Nutritional regulation of mRNA processing.

Salati LM, Szeszel-Fedorowicz W, Tao H, Gibson MA, Amir-Ahmady B, Stabile LP, Hodge DL.

J Nutr. 2004 Sep;134(9):2437S-2443S. Review.


Estrogen receptor pathways in lung cancer.

Stabile LP, Siegfried JM.

Curr Oncol Rep. 2004 Jul;6(4):259-67. Review.


Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung.

Siegfried JM, Luketich JD, Stabile LP, Christie N, Land SR.

Chest. 2004 May;125(5 Suppl):116S-9S. No abstract available.


Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy.

Stabile LP, Lyker JS, Huang L, Siegfried JM.

Gene Ther. 2004 Feb;11(3):325-35.


Sex and gender differences in lung cancer.

Stabile LP, Siegfried JM.

J Gend Specif Med. 2003;6(1):37-48. Review.


Inhibition of the splicing of glucose-6-phosphate dehydrogenase precursor mRNA by polyunsaturated fatty acids.

Tao H, Szeszel-Fedorowicz W, Amir-Ahmady B, Gibson MA, Stabile LP, Salati LM.

J Biol Chem. 2002 Aug 23;277(34):31270-8. Epub 2002 Jun 18.

Supplemental Content

Loading ...
Support Center